DAWN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

44.10M

+51.03%

-0.201

-68.09%

50.86M

+65.35%

-0.190

-45.71%

55.58M

+63.92%

-0.143

-50.58%

Estimates Revision

The market is revising Downward the revenue expectations for Day One Biopharmaceuticals, Inc. (DAWN) for FY2025, with the revenue forecasts being adjusted by -0.11% over the past three months. During the same period, the stock price has changed by 14.83%.

Revenue Estimates for FY2025

Revise Downward

-0.11%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.05%

In Past 3 Month

Stock Price

Go Up

+14.83%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is 23.57 USD with a low forecast of 16.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 8.245

Low

16.00

Averages

23.57

High

34.00

Current: 8.245

Low

16.00

Averages

23.57

High

34.00

JPMorgan

NULL -> Overweight

maintain

$26 -> $27

2025-11-07

Reason

JPMorgan

Price Target

$26 -> $27

2025-11-07

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Day One Biopharmaceuticals to $27 from $26 and keeps an Overweight rating on the shares. The firm updated the company's model.

Piper Sandler

Overweight

maintain

$25 -> $26

2025-11-05

Reason

Piper Sandler

Price Target

$25 -> $26

2025-11-05

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Day One Biopharmaceuticals to $26 from $25 and keeps an Overweight rating on the shares following quarterly results. The firm thinks valuation provides an attractive entry point into Day One ahead of continued commercial execution, additional long-term data, and eventual 1L pLGG data in 2027.

Piper Sandler

Overweight

initiated

$25

2025-08-19

Reason

Piper Sandler

Price Target

$25

2025-08-19

initiated

Overweight

Reason

Piper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target. Piper thinks the stock move following the first two 2025 earnings reports is overdone and that these early decelerations of Ojemda are artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies, the analyst tells investors in a research note. The firm continues to believe the clinical data will support strong penetration longer term.

Piper Sandler

Overweight

initiated

$25

2025-08-18

Reason

Piper Sandler

Price Target

$25

2025-08-18

initiated

Overweight

Reason

Piper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target.

H.C. Wainwright

Andres Maldonado

Buy

downgrade

$36 -> $25

2025-08-06

Reason

H.C. Wainwright

Andres Maldonado

Price Target

$36 -> $25

2025-08-06

downgrade

Buy

Reason

H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Day One Biopharmaceuticals to $25 from $36 and keeps a Buy rating on the shares following the Q2 report. The firm reduced estimates for the Ojemda launch.

BofA

Buy

downgrade

$20 -> $17

2025-08-06

Reason

BofA

Price Target

$20 -> $17

2025-08-06

downgrade

Buy

Reason

BofA lowered the firm's price target on Day One Biopharmaceuticals to $17 from $20 and keeps a Buy rating on the shares. The firm estimates approximately 25-35 new patients added per month in Q1 and assuming a flat growth rate of patients over the quarter sees about 18 new patient starts per month in Q2, which it calls out as "significantly less than the lower end of our estimate in 1Q." The new FY25 guidance of $140M-$150M net product revenue "seems to reflect a slowdown in growth," which will be something to watch as Day One focuses on improving both breadth and depth of prescriber adoption, the analyst added.

Valuation Metrics

The current forward P/E ratio for Day One Biopharmaceuticals Inc (DAWN.O) is -13.92, compared to its 5-year average forward P/E of -8.26. For a more detailed relative valuation and DCF analysis to assess Day One Biopharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.26

Current PE

-13.92

Overvalued PE

-4.77

Undervalued PE

-11.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.21

Current EV/EBITDA

-3.89

Overvalued EV/EBITDA

-0.88

Undervalued EV/EBITDA

-9.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

474.44

Current PS

4.01

Overvalued PS

2319.29

Undervalued PS

-1370.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DAWN News & Events

Events Timeline

No data

News

8.5

12-10Globenewswire

Mersana to be Acquired by Day One for Up to $55.25 per Share Amid Investigation

4.0

11-24Benzinga

Needham Affirms Buy Rating for Day One Biopharmaceutical, Keeps $16 Price Target Intact

8.5

11-13Benzinga

Day One Biopharma Enhances Oncology Portfolio Through $285 Million Acquisition of Mersana

People Also Watch

Frequently Asked Questions

What is Day One Biopharmaceuticals Inc (DAWN) stock price today?

The current price of DAWN is 8.245 USD — it has decreased -1.38 % in the last trading day.

What is Day One Biopharmaceuticals Inc (DAWN)'s business?

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

What is the price predicton of DAWN Stock?

What is Day One Biopharmaceuticals Inc (DAWN)'s revenue for the last quarter?

Day One Biopharmaceuticals Inc revenue for the last quarter amounts to 39.80M USD, decreased -57.56 % YoY.

What is Day One Biopharmaceuticals Inc (DAWN)'s earnings per share (EPS) for the last quarter?

Day One Biopharmaceuticals Inc. EPS for the last quarter amounts to -0.19 USD, decreased -150.00 % YoY.

What changes have occurred in the market's expectations for Day One Biopharmaceuticals Inc (DAWN)'s fundamentals?

How many employees does Day One Biopharmaceuticals Inc (DAWN). have?

Day One Biopharmaceuticals Inc (DAWN) has 181 emplpoyees as of December 15 2025.

What is Day One Biopharmaceuticals Inc (DAWN) market cap?

Today DAWN has the market capitalization of 858.37M USD.